top of page

IIT vs. IND: What China's Dual-Track Model Teaches Us About Clinical Development Strategy

  • Paulo Cesar Fernandes
  • 3 hours ago
  • 2 min read


The development of Cell and Gene Therapies (CGT) demands a speed of scientific iteration that traditional drug development regulatory pathways often cannot keep up with. To address this, China has adopted a unique regulatory system known as Dual-Track , which separates studies into two distinct pathways: IIT ( Investigator-Initiated Trials ) and IND ( Investigational New Drug ).


Understanding this model and knowing how to connect it to Brazil's new regulatory reality is key to designing highly efficient global clinical development strategies.


The Dual-Track Model: Speed vs. Recording Rigor


In China, advanced therapies can follow two routes:

  1. The Medical Technology Initiation (IIT) Pathway: Treats the product as a medical technology under the supervision of the National Health Commission (NHC). Studies are initiated by qualified investigators within accredited hospital institutions. They do not require approval from the National Health Agency (NMPA), only from the local ethics committee. Result: Incredible speed to the first patient, high flexibility to adjust doses, and rapid generation of proof-of-concept (PoC) signals.

  2. The Biological Pathway (IND): Treats the product as a drug under NMPA/CDE regulation, specifically focused on registration and marketing. It is a slow, expensive process with a high regulatory burden.



How to Connect the IIT/IND Route (equivalent) to Brazil


The mistake many sponsors make is viewing IIT and IND as competing paths. In reality, they are complementary and sequential. A smart global clinical development strategy utilizes the best of both worlds.


With the new Legal Framework in Brazil, the country has become the perfect destination to receive the baton after the IIT phase in China. Once the Chinese biotech company validates safety and dosage in a fast IIT in Shanghai or Beijing, it can directly submit a dossier in Brazil, leveraging the Brazilian regulatory agency (an ICH member) to conduct registration studies at costs up to 60% lower than in the US.

 
 
 

Comments

bottom of page